Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 7 » Supplement 1

Noradrenergic symptom cluster in depression

Authors Montgomery S, Briley M

Published 31 May 2011 Volume 2011:7(Supplement 1) Pages 1—2

DOI https://dx.doi.org/10.2147/NDT.S19611

Stuart Montgomery1, Mike Briley2
1Imperial College School of Medicine, London, UK; 2NeuroBiz Consulting and Communication, Castres, France
Depression is characterized by a wide range of diverse symptoms, the severity of which can be quantified by various depression rating scales, such as the Montgomery Asberg Depression Rating Scale. Analyses of the individual items of this scale in patients treated with the selective serotonin reuptake inhibitors (SSRIs) have shown that not all items respond equally or with the same time of onset of improvement (Table 1).1,2 The items which respond less well or more slowly with SSRIs include lassitude, loss of energy, retardation of thoughts or actions, as well as concentration difficulties and loss of alertness. The loss of interest or pleasure that depressed patients experience (anhedonia) also responds poorly to SSRIs, and patients often complain of emotional indifference or blunting. Certain sleep difficulties are sometimes worsened by SSRIs. Appetite loss can be aggravated by certain SSRIs, an effect which can be made worse by nausea at the beginning of treatment.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Choking risk among psychiatric inpatients

Nagamine T

Neuropsychiatric Disease and Treatment 2011, 7:381-382

Published Date: 20 June 2011

The noradrenergic symptom cluster: clinical expression and neuropharmacology

Blier P, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:15-20

Published Date: 3 June 2011

Improvement of the noradrenergic symptom cluster following treatment with milnacipran

Kasper S, Meshkat D, Kutzelnigg A

Neuropsychiatric Disease and Treatment 2011, 7:21-27

Published Date: 31 May 2011

The increasing burden of depression

Lépine J-P, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:3-7

Published Date: 31 May 2011

The importance of norepinephrine in depression

Moret C, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:9-13

Published Date: 31 May 2011

Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities

Miho Takenoshita, Tomoko Sato, Yuichi Kato, et al

Neuropsychiatric Disease and Treatment 2010, 6:699-705

Published Date: 13 October 2010

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors

Mike Briley, Chantal Moret

Neuropsychiatric Disease and Treatment 2010, 6:647-655

Published Date: 23 September 2010

Treatment of patients with comorbid depression and diabetes with metformin and milnacipran

Peter Hofmann

Neuropsychiatric Disease and Treatment 2010, 6:9-15

Published Date: 25 August 2010

Antidepressant therapy with milnacipran and venlafaxine

Lucilla Mansuy

Neuropsychiatric Disease and Treatment 2010, 6:17-22

Published Date: 25 August 2010

Milnacipran: a unique antidepressant?

Siegfried Kasper, Gerald Pail

Neuropsychiatric Disease and Treatment 2010, 6:23-31

Published Date: 25 August 2010

Milnacipran: recent findings in depression

Guest editors: Stuart Montgomery (London, UK) and Mike Briley (Castres, France)

Neuropsychiatric Disease and Treatment 2010, 6:0-0

Published Date: 24 August 2010

Editorial Foreword - Milnacipran: recent findings in depression

Stuart Montgomery, Mike Briley

Neuropsychiatric Disease and Treatment 2010, 6:1-2

Published Date: 24 August 2010

Readers of this article also read:

Spotlight on tavaborole for the treatment of onychomycosis

Jinna S, Finch J

Drug Design, Development and Therapy 2015, 9:6185-6190

Published Date: 20 November 2015

Aloe vera gel facilitates re-epithelialization of corneal alkali burn in normal and diabetic rats

Atiba A, Wasfy T, Abdo W, Ghoneim A, Kamal T, Shukry M

Clinical Ophthalmology 2015, 9:2019-2026

Published Date: 28 October 2015

Caval filters in intensive care: a retrospective study

Ferraro F, Di Gennaro TL, Torino A, Petruzzi J, d'Elia A, Fusco P, Marfella R, Lettieri B

Drug Design, Development and Therapy 2014, 8:2213-2219

Published Date: 6 November 2014

Lumbar facet injection for the treatment of chronic piriformis myofascial pain syndrome: 52 case studies

Huang JT, Chen HY, Hong CZ, Lin MT, Chou LW, Chen HS, Tsai CT, Chang WD

Patient Preference and Adherence 2014, 8:1105-1111

Published Date: 20 August 2014

Meta-analysis of the ocular biocompatibility of a new multipurpose lens care system

Reindel W, Merchea MM, Rah MJ, Zhang L

Clinical Ophthalmology 2013, 7:2051-2056

Published Date: 14 October 2013

A novel dimeric thymosin beta 4 with enhanced activities accelerates the rate of wound healing

Xu TJ, Wang Q, Ma XW, Zhang Z, Zhang W, Xue XC, Zhang C, Hao Q, Li WN, Zhang YQ, Li M

Drug Design, Development and Therapy 2013, 7:1075-1088

Published Date: 1 October 2013

Limitations of using synthetic blood clots for measuring in vitro clot capture efficiency of inferior vena cava filters

Robinson RA, Herbertson LH, Sarkar Das S, Malinauskas RA, Pritchard WF, Grossman LW

Medical Devices: Evidence and Research 2013, 6:49-57

Published Date: 10 May 2013

Erratum

Utine CA

Clinical Ophthalmology 2011, 5:1415-1416

Published Date: 28 September 2011